Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics
AbstractThe Paramyxoviridae genus Henipavirus is presently represented by the type species Hendra and Nipah viruses which are both recently emerged zoonotic viral pathogens responsible for repeated outbreaks associated with high morbidity and mortality in Australia, Southeast Asia, India and Bangladesh. These enveloped viruses bind and enter host target cells through the coordinated activities of their attachment (G) and class I fusion (F) envelope glycoproteins. The henipavirus G glycoprotein interacts with host cellular B class ephrins, triggering conformational alterations in G that lead to the activation of the F glycoprotein, which facilitates the membrane fusion process. Using the recently published structures of HeV-G and NiV-G and other paramyxovirus glycoproteins, we review the features of the henipavirus envelope glycoproteins that appear essential for mediating the viral fusion process, including receptor binding, G-F interaction, F activation, with an emphasis on G and the mutations that disrupt viral infectivity. Finally, recent candidate therapeutics for henipavirus-mediated disease are summarized in light of their ability to inhibit HeV and NiV entry by targeting their G and F glycoproteins. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Steffen, D.L.; Xu, K.; Nikolov, D.B.; Broder, C.C. Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics. Viruses 2012, 4, 280-308.
Steffen DL, Xu K, Nikolov DB, Broder CC. Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics. Viruses. 2012; 4(2):280-308.Chicago/Turabian Style
Steffen, Deborah L.; Xu, Kai; Nikolov, Dimitar B.; Broder, Christopher C. 2012. "Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics." Viruses 4, no. 2: 280-308.